This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
The annual congress of Biology and Health PhD students from Lille (André Verbert day) took place at the Faculty of Medicine Thursday, September 10th. During this day, PhD students, in third year of thesis, had Read more…
Ask for high quality link by putting your email below We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs Read more…
In HCS Pharma, we have alreadytalked about Artificial Intelligence (AI) and the way it is useful in picture analysis. AI can obviously be used for many endeavours, like the shortening of drug discovery timeline as Read more…
Last week we were glad to attend TERMIS-EU workshop in Nantes, dealing with 3D bioprinting in cancer research. There we presented 3 posters – that you can find on our website! – about BIOMIMESYS® product Read more…
We are very happy to be a part of the innovation landscape in France and to be supported (very efficiently) by BPI France. This year again we will be present at the big “Bpifrance Inno Read more…
Ask for high quality link by putting your email below Objective: to develop a new liver-on-chip model that includes a relevant 3D matrix for hepatic cell growth and function with the use of of BIOMIMESYS® Read more…
We will attend Termis workshop (August 26-27 in Nantes, France) to present our innovations on 3D cell culture and, of course, our brand new BIOMIMESYS® products! In our new poster, you will find how we Read more…
The extracellular matrix (ECM) is known as a molecular network of macromolecules present in all solid tissues (Figure 1), which plays an important role in the growth, migration and differentiation of cells. This ECM is Read more…
There are many things to perform today using Artificial Intelligence (AI), especially in health and drug discovery domains (but only if you understand the technologies!). If you want to improve your knowledge in the field Read more…
We were invited at the workshop organized by SMILL-E (Seeding Microsystems in Medecine in Lille – European-Japanese Technologies against Cancer) and Yncrea during MedFit event last week. This great workshop was about Digital and Micro Read more…
Atopic dermatitis (AD) is a chronic, common inflammatory skin disease affecting 15-20% of children and 1-3% of adults worldwide. Loss of bacterial diversity from excess abundance of Staphylococcus aureus is associated with increased disease severity, Read more…
It was a great pleasure to be invited (thanks to our partner Molecular Devices) to present our work during these 2 events organized by selectBio in Rotterdam: Organoids and Tox Screening Europe 2019 on June Read more…
Elodie, Véronique et Océane ont profité d’un moment très sympathique – et ensoleillé – lors du barbecue du parc Eurasanté ce midi… Merci à tous, et bon week-end 🙂
In the continuity of our scientific reviews about the important roles of Hyaluronic Acid (HA) in extracellular matrix (ECM) and cell behavior, we herein present this recent review describing the structure – function relationship of Read more…
Last week we were pleased to attend the founding congress of STCM (Société de Toxicologie Cellularie et Moléculaire), which was held in FIAP Jean Monnet (Paris). The topic was “Toxicology towards the 3rd dimension“. With Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
HCS Pharma – Site de Rennes
Biopole
6 Rue Pierre Joseph Colin
35000 RENNES
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.